Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Telithromycin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 1.00 |
| ▸ | CYP3A5 | P20815 | 6/20 | 1.00 |
| ▸ | CYP3A7 | P24462 | 6/20 | 1.00 |
| ▸ | CYP3A43 | Q9HB55 | 6/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 1.00 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 1.00 |
| ▸ | GNRHR | P30968 | 2/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.51 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.51 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.51 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Telithromycin SCHEMBL19518975 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP3A5CYP3A7CYP3A43KCNH2 | |
| Telithromycin SCHEMBL14521662 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP3A5CYP3A7CYP3A43KCNH2 | |
| Telithromycin SCHEMBL784845 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP3A5CYP3A7CYP3A43KCNH2 | |
| Telithromycin SCHEMBL18035669 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP3A5CYP3A7CYP3A43KCNH2 | |
| Telithromycin SCHEMBL12858721 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP3A5CYP3A7CYP3A43KCNH2 | |
| Telithromycin SCHEMBL14268636 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP3A5CYP3A7CYP3A43KCNH2 | |
| Telithromycin SCHEMBL10819900 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP3A5CYP3A7CYP3A43KCNH2 | |
| Telithromycin SCHEMBL15387603 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP3A5CYP3A7CYP3A43KCNH2 | |
| Telithromycin SCHEMBL1878591 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP3A5CYP3A7CYP3A43KCNH2 | |
| Telithromycin SCHEMBL31576166 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP3A5CYP3A7CYP3A43KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 17535 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| US-12629363-B2 | Prophylaxis and treatment of angioedema | PHARVARIS GMBH (CH) | 2026-05-19 | — | — | US | claimed |
| WO-2026102345-A1 | METHODS OF ADMINISTERING THE VOLTAGE-GATED POTASSIUM CHANNEL OPENER AZETUKALNER | XENON PHARMACEUTICALS INC. (CA) | 2026-05-15 | — | — | WO | claimed |
| CN-122012565-A | Apramycin genetically engineered bacterium with genetic stability, construction method and application thereof | 天津科技大学 | 2026-05-12 | — | — | CN | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| EP-3790536-B1 | NANOCONTAINERS FOR TRANSPORTING NONPOLAR, LIPOPHILIC SUBSTANCES SUCH AS ANTIBIOTICS | KARLSRUHER INST TECHNOLOGIE (DE) | 2026-04-22 | — | — | EP | claimed |
| EP-4724062-A2 | COMPOSITIONS AND METHODS FOR INCREASING EXPOSURE OF R(-)-MDA | EmpathBio, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| WO-2004017925-A2 | METHODS AND REAGENTS FOR PREVENTING BACTEREMIAS | GENOME THERAPEUTICS CORPORATION (US) | 2004-03-04 | — | — | WO | claimed |
| WO-2004009059-A1 | TASTE MASKED ORAL COMPOSITION OF TELITHROMYCIN | AVENTIS PHARMA S.A. (FR) | 2004-01-29 | — | — | WO | claimed |
| US-20040013737-A1 | Taste masked oral composition of telithromycin | AVENTIS PHARMA S.A. (FR) | 2004-01-22 | — | — | US | claimed |
| US-20030236265-A1 | Methods of treating bacterial infections and diseases associated therewith | ACTIVBIOTICS PHARMA LLC | 2003-12-25 | — | — | US | claimed |
| WO-2003099217-A2 | METHODS OF TREATING BACTERIAL INFECTIONS AND DISEASES ASSOCIATED THEREWITH | ACTIVBIOTICS, INC. (US) | 2003-12-04 | — | — | WO | claimed |
| EP-1212336-B1 | METHOD FOR THE PRODUCTION AND USE OF SPHERICAL TELITHROMYCIN CLUSTERS IN THE PREPARATION OF PHARMACEUTICAL FORMS | AVENTIS PHARMA SA (FR) | 2003-12-03 | — | — | EP | claimed |
| US-20030082107-A1 | Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer | NOVADEL PHARMA INC. | 2003-05-01 | — | — | US | claimed |
| US-20020177559-A1 | Quinolone derivatives | WOCKHARDT LIMITED | 2002-11-28 | — | — | US | claimed |
| CN-1371386-A | Spherical telithromycikn clusters, method for the production and use thereof in the preparation of pharmaceutical forms | AVENTIS PHARMA SA (FR) | 2002-09-25 | — | — | CN | claimed |
| WO-2001093904-A1 | METHOD OF TREATING GASTROINTESTINAL DISEASES ASSOCIATED WITH SPECIES OF GENUS CLOSTRIDIUM | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2001-12-13 | — | — | WO | claimed |